Tuesday, October 5, 2010

DailyMarkets.com - A Telling Tapestry Of Numbers And Narrative

DailyMarkets.com - A Telling Tapestry Of Numbers And Narrative


A Telling Tapestry Of Numbers And Narrative

Posted: 05 Oct 2010 05:45 PM PDT

Here at Financial Armageddon, I sift through all sorts of data to try and assess where things stand and where they might be headed. As with some (though certainly not all) economists and Wall Street analysts, I analyze a variety of statistics, data points. and trends.
I also try to factor in other information that I pick up during my daily routine, including personal observations, anecdotes from acquaintances and friends, and reports that focus on the faces behind the figures.
In my view, this … [visit site to read more]


J&J Chronic Pain Drug Faces CRL

Posted: 05 Oct 2010 04:35 PM PDT

Johnson & Johnson (NYSE:JNJ) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the company's moderate-to-severe chronic pain treatment Nucynta (tapentadol).
 
The drug is already in the market as an immediate release formulation for the treatment of moderate-to-severe chronic pain in patients 18 years and older. The CRL applies for the New Drug Application (NDA) for tapentadol to be marketed as an extended release (ER) … [visit site to read more]


J&J Chronic Pain Drug Faces CRL

Posted: 05 Oct 2010 04:35 PM PDT

Johnson & Johnson (NYSE:JNJ) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the company's moderate-to-severe chronic pain treatment Nucynta (tapentadol).
 
The drug is already in the market as an immediate release formulation for the treatment of moderate-to-severe chronic pain in patients 18 years and older. The CRL applies for the New Drug Application (NDA) for tapentadol to be marketed as an extended release (ER) … [visit site to read more]


J&J Chronic Pain Drug Faces CRL

Posted: 05 Oct 2010 03:05 PM PDT

Johnson & Johnson (NYSE:JNJ) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the company's moderate-to-severe chronic pain treatment Nucynta (tapentadol).
 
The drug is already in the market as an immediate release formulation for the treatment of moderate-to-severe chronic pain in patients 18 years and older. The CRL applies for the New Drug Application (NDA) for tapentadol to be marketed as an extended release (ER) … [visit site to read more]


Boeing Gets Another Bulk Order

Posted: 05 Oct 2010 03:05 PM PDT

The Boeing Company (NYSE:BA) will supply 60 737-800 airplanes to Air Lease Corporation through 2017. Of the orders bagged, 54 are firm orders while the remaining 6 require reconfirmation.

Entering into the fourth quarter, this is the second order Boeing received for supplying 737-800 airplanes. Recently, Luxair Luxembourg Airlines, the national carrier of the Grand Duchy of Luxembourg, ordered an additional 737-800 airplanes. The 737-800 has an average list price of $77 million.

The company's … [visit site to read more]


AES Expands In The Philippines

Posted: 05 Oct 2010 02:35 PM PDT

In an effort to meet the increasing demand for electricity in the Philippines, The AES Corporation (NYSE:AES) plans to expand its Masinloc power generation facility. The company estimates a capital investment of approximately $800 million, obtained from a combination of non-recourse financing and equity. The company plans to double the size of its 660 megawatt Masinloc I coal-fired power plant.

The company noted that the growing power sector in the Philippines requires new low-cost electric … [visit site to read more]


Swiss Propose Strict Capital Rules

Posted: 05 Oct 2010 02:35 PM PDT

According to a proposal made by the Swiss government committee this Monday, Swiss banking giants UBS AG (NYSE:UBS) and Credit Suisse Group (NYSE:CS) will need to retain more capital in reserve. The proposal, which is supported by the Swiss National Bank and the country’s financial regulator FINMA, would now require the parliament's approval. The requirements are said to exceed the levels set by the international standards, Basel III.

Capital Requirements
As per the proposal, UBS and Credit Suisse … [visit site to read more]


J&J Chronic Pain Drug Faces CRL

Posted: 05 Oct 2010 02:05 PM PDT

Johnson & Johnson (NYSE:JNJ) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the company's moderate-to-severe chronic pain treatment Nucynta (tapentadol).
 
The drug is already in the market as an immediate release formulation for the treatment of moderate-to-severe chronic pain in patients 18 years and older. The CRL applies for the New Drug Application (NDA) for tapentadol to be marketed as an extended release (ER) … [visit site to read more]


Potential For Myriad’s Bracanalysis

Posted: 05 Oct 2010 01:05 PM PDT

Myriad Genetics (NASDAQ:MYGN) presented preliminary results from a study conducted on breast cancer patients at the ASCO Breast Cancer Symposium. The study found that the incidence of BRCA germline mutations is higher in women with triple negative breast cancer (TNBC). Consequently, the need to screen women with TNBC is higher thereby increasing the importance of Bracanalysis testing.
Myriad's Bracanalysis provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing a woman’s risk of … [visit site to read more]


SWK Downgraded To Neutral

Posted: 05 Oct 2010 12:35 PM PDT

We recently downgraded our rating for Stanley Black & Decker (NYSE:SWK), manufacturer of tools and engineered security solutions, from Outperform to a Neutral recommendation. Factors including integration risks, rising competition and financial burden were the prime reasons for the downgrade.
 
Second Quarter Highlights
 
Stanley Black & Decker reported its EPS of $1.03 in the second quarter of 2010, compared with $0.55 in the year ago quarter, representing a year-over-year … [visit site to read more]


Navigant Acquires EthosPartners

Posted: 05 Oct 2010 12:35 PM PDT

Further enhancing its healthcare consulting practice, Navigant Consulting Inc. (NCI) recently announced the acquisition of EthosPartners Healthcare Management Group Inc., a national healthcare consulting group.
 
Navigant has agreed to pay a total sum of $37 million, including $28 million in cash, $2 million in restricted Navigant stock and $7 million of deferred cash payments. EthosPartners can also earn up to $8 million more based on the future performance of the … [visit site to read more]


Kinetic Initiated At Neutral

Posted: 05 Oct 2010 12:05 PM PDT

Recently, we initiated our coverage on Kinetic Concepts, Inc. (NYSE:KCI) with a Neutral rating.
 
Kinetic reported an adjusted EPS of $1.01, beating the Zacks Consensus Estimate of $0.97 and the year-ago quarter's $0.98. Net sales (including rental income) of the company increased 1.3% to $497.8 million with a 3.1% decline in rental income to $283.1 million. A 2.7% revenue growth of the North American market was offset by a 3.5% decline of the EMEA/APAC market due to unfavorable currency … [visit site to read more]


Sometimes It Is That Simple

Posted: 05 Oct 2010 12:05 PM PDT

The #1 problem for investors is “information overload.” There are just so many different potential investment strategies to follow. Each of them claiming to be the best route to success. And then you have countless places to get this information: TV, Internet, magazines, books, friends/family, etc.

When you consider this landscape, it’s no wonder the stock market is more volatile these days given all the different forces at work that drive the varied investor decisions.

So let me provide you … [visit site to read more]


Dr Pepper’s License Deal

Posted: 05 Oct 2010 12:05 PM PDT

Dr Pepper Snapple Group Inc. (NYSE:DPS) announced the completion of the transaction with The Coca-Cola Company (NYSE:KO) to license some of its brands. The agreement grants Coca-Cola the distribution rights for Dr Pepper in the U.S. and Canada Dry in North East U.S. for a one-time payment of $715 million. Dr Pepper Snapple has plans to use a fraction of the cash proceeds to augment its share repurchase program. 
The 20-year deal (with a provision for 20-year renewals) with Dr Pepper Snapple … [visit site to read more]


INVOcell Launched In Canada

Posted: 05 Oct 2010 12:05 PM PDT

On October 5, 2010, INVO Biosciences (IVOB) announced that it has signed an agreement with Canadian-based Invaron Pharmaceuticals for the exclusive distribution of INVOcell in Canada. We believe this could represent a meaningful near-term revenue driver for INVO Bio, given the growing infertility rates in Canada and recently implemented reimbursement policy that dramatically improves patient access to assisted reproductive procedures.

INVO Bio received Health Canada Regulatory Approval … [visit site to read more]


Value Investor Joel Greenblatt Launches New Fund

Posted: 05 Oct 2010 12:03 PM PDT

Joel Greenblatt is confident he can do it again. The famed value investor, whose Gotham Capital hedge fund earned average annualized returns (before fees) in excess of 50 percent in the ten years of its existence, is launching Gotham Asset Management, a New York-based firm that will offer value-focused funds to institutional and retail investors. It is the first time Greenblatt will be running institutional money since 1994, when he closed his former fund and returned capital to outside … [visit site to read more]


Top Pay For MLB Players Is Out Of Control

Posted: 05 Oct 2010 12:01 PM PDT

The CNBC discussion above focuses on the question of whether CEO pay is “out of control.”  LA Times business writer Michael Hiltizk say Yes, and in a recent LA Times article he cited this Harvard Magazine article that reports that the “Ratio of Average CEO Pay to Average Worker Pay” has increased from 107:1 in 1990 to 344:1 in 2007. 

Big deal. The ratio of the median salary of the top 25 highest-paid Major League Baseball players to the median U.S. household income has … [visit site to read more]


71% Odds Of At Least +45 Seats For Republicans

Posted: 05 Oct 2010 11:52 AM PDT

The chart above is from this website and summarizes the current Intrade betting odds for various gains in House seats for Republicans.  Intrade contracts which are trading above 50% odds are shaded dark red, and contracts below 50% are a lighted shade.  As of today, there is 71% chance that the Republicans will gain at least 45 seats. 

The same website is showing a net gain of 8 Senate seats for the Republicans (AZ, CO, IL, IN, ND, PA, WI … [visit site to read more]


No comments:

Post a Comment